Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020

About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to C. auris clinical isolates but not for New Jersey, highlighting the regional differences. About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to C. auris clinical isolates but not for New Jersey, highlighting the regional differences.

Automated summary

Around 55% of U.S. Candida auris clinical cases were reported in New York and New Jersey from 2016 to 2020. Almost all clinical isolates from New York and New Jersey (99.8%) were resistant to fluconazole, and 50% were resistant to amphotericin B. Echinocandin resistance increased from 0% to 4%, and pan-resistance increased from 0 to C. auris clinical isolates, but not in New Jersey, highlighting regional differences.